AML
MCID: LKM061
MIFTS: 73

Leukemia, Acute Myeloid (AML) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Leukemia, Acute Myeloid

About this section

Aliases & Descriptions for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 52 35
Acute Myeloid Leukemia 35 11 48 24 70 27 38 13
Acute Myelogenous Leukemia 11 48 24 13
Leukemia, Acute Myelogenous 24 70 12
Acute Myeloblastic Leukemia 11 70
Leukemia, Myelocytic, Acute 11 68
Aml 24 70
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 52
 
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 52
Leukemia, Acute Myeloid, Somatic 52
Acute Non-Lymphoblastic Leukemia 70
Acute Non-Lymphocytic Leukemia 70
Aml - Acute Myeloid Leukemia 11
Acute Myelocytic Leukemia 70
Leukemia, Myeloid, Acute 39
Leukemia, Acute Myeloie 52

Characteristics:

HPO:

64
leukemia, acute myeloid:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 601626
Disease Ontology11 DOID:9119
ICD9CM32 205.0
MeSH39 D015470

Summaries for Leukemia, Acute Myeloid

About this section
MedlinePlus:38 Leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, however, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in acute myeloid leukemia (aml), there are too many of a specific type of white blood cell called a myeloblast. aml is the most common type of acute leukemia in adults. this type of cancer usually gets worse quickly if it is not treated. possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. symptoms of aml include: fever shortness of breath easy bruising or bleeding bleeding under the skin weakness or feeling tired weight loss or loss of appetite tests that examine the blood and bone marrow diagnose aml. treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. once the leukemia is in remission, you need additional treatment to make sure that it does not come back. nih: national cancer institute

MalaCards based summary: Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute leukemia and acute myeloblastic leukemia without maturation, and has symptoms including angina pectoris, angina pectoris and chest pain. An important gene associated with Leukemia, Acute Myeloid is JAK2 (Janus Kinase 2), and among its related pathways are NF-kappaB Signaling and Endometrial cancer. The drugs cyclophosphamide and etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are mortality/aging and neoplasm.

Disease Ontology:11 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases:48 Acute myeloid leukemia (aml) is a cancer that affects the blood and bone marrow. conditions are generally called "acute" when they develop quickly and have an aggressive course. the signs and symptoms of aml vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. aml is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. there are many potential causes of aml such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop aml have no identifiable risk factor. treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy. last updated: 10/29/2015

UniProtKB/Swiss-Prot:70 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia:71 Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid... more...

Description from OMIM:52 601626

Related Diseases for Leukemia, Acute Myeloid

About this section

Diseases in the Myeloid Leukemia family:

leukemia, acute myeloid Acute Myeloid Leukemia, Flt3-Related
Acute Myeloid Leukemia, Kit-Related Npm1-Related Acute Myeloid Leukemia
Inherited Acute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 78)
idRelated DiseaseScoreTop Affiliating Genes
1acute leukemia32.3FLT3, MLLT10
2acute myeloblastic leukemia without maturation12.5
3cytogenetically normal acute myeloid leukemia12.5
4core binding factor acute myeloid leukemia12.5
5familial acute myeloid leukemia with mutated cebpa12.4
6acute myeloblastic leukemia with maturation12.3
7acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)12.3
8familial platelet disorder with propensity to acute myelogenous leukemia12.2
9therapy related acute myeloid leukemia and myelodysplastic syndrome12.1
10acute myeloid leukemia with t(9;11)(p22;q23)12.1
11acute myeloid leukemia with t(8;16)(p11;p13) translocation12.1
12acute myeloid leukemia with t(6;9)(p23;q34)12.1
13acute myeloid leukemia with minimal differentiation12.1
14cebpa-associated familial acute myeloid leukemia12.1
15acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)12.0
16inherited acute myeloid leukemia12.0
17acute myeloid leukemia with recurrent genetic anomaly12.0
18acute myeloid leukemia and myelodysplastic syndromes related to radiation12.0
19acute myeloid leukemia with cebpa somatic mutations12.0
20megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)12.0
21acute myeloid leukemia with npm1 somatic mutations12.0
22acute myeloid leukemia with 11q23 abnormalities12.0
23acute myeloid leukemia with t(8;21)(q22;q22) translocation12.0
24acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent12.0
25acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor12.0
26aml with myelodysplasia-related features11.8
27platelet disorder, familial, with associated myeloid malignancy11.8
28leukemia11.4
29megakaryocytic leukemia11.1
30acute non lymphoblastic leukemia11.1
31acute myeloid leukemia, flt3-related11.0
32cranioectodermal dysplasia 110.9CEBPA, CHIC2, DNMT3A, ETV6, FLT3, GATA2
33agammaglobulinemia 8, autosomal dominant10.7CEBPA, DNMT3A, ETV6, FLT3, GATA2, IDH1
34hemophagocytic lymphohistiocytosis10.7ETV6, FLT3, GATA2, JAK2, KIT, MLLT10
35milker's nodule10.7CEBPA, DNMT3A, ETV6, FLT3, KIT, NPM1
36liver disease10.7CEBPA, ETV6, FLT3, JAK2, KIT, MLLT10
37acute respiratory distress syndrome10.7CEBPA, FLT3, GATA2, JAK2, KIT, NPM1
38acute lymphocytic leukemia10.6CEBPA, ETV6, FLT3, JAK2, KIT, MLLT10
39phosphoserine phosphatase deficiency10.6ETV6, FLT3, GATA2, MLLT10, NUP214, PICALM
40familial hyperaldosteronism10.6CEBPA, FLT3, JAK2, KIT, KRAS, RUNX1
41peroxisome biogenesis disorder 7a10.6ETV6, FLT3, GATA2, JAK2, KIT, RUNX1
42glycogen storage disease type 010.6CEBPA, FLT3, IDH1, IDH2, NPM1
43colorectal adenoma10.6DNMT3A, ETV6, FLT3, JAK2, RUNX1
44actinobacillosis10.6ETV6, FLT3, JAK2, KIT, RUNX1
45amblyopia10.6ETV6, FLT3, JAK2, PICALM, RUNX1
46unilateral hemispheric polymicrogyria10.6CEBPA, FLT3, KIT, RUNX1
47adducted thumbs dundar type10.6ETV6, FLT3, KIT, RUNX1
48medullary cystic kidney disease 110.6FLT3, GATA2, KRAS, RUNX1
49mild canavan disease10.6CEBPA, GATA2, TGM6
50neurofibromatosis10.6FLT3, KIT, NPM1

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to leukemia, acute myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

About this section

Symptoms by clinical synopsis from OMIM:

601626

Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

 64
id Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia64 HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

41 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076811.5CEBPA, CHIC2, DNMT3A, ETV6, FLT3, GATA2
2MP:000200611.4CEBPA, ETV6, FLT3, IDH2, JAK2, KIT
3MP:000537611.4CEBPA, DNMT3A, ETV6, FLT3, GATA2, IDH1
4MP:000538411.4CEBPA, DNMT3A, ETV6, FLT3, GATA2, JAK2
5MP:000538011.3DNMT3A, ETV6, GATA2, JAK2, KIT, KRAS
6MP:000537811.3CEBPA, DNMT3A, ETV6, FLT3, GATA2, IDH1
7MP:000538711.2CEBPA, ETV6, FLT3, IDH1, JAK2, KIT
8MP:000539011.2FLT3, IDH1, IDH2, JAK2, KIT, KRAS
9MP:000287311.1CEBPA, ETV6, GATA2, JAK2, KIT, KRAS
10MP:000537911.0CEBPA, DNMT3A, ETV6, FLT3, GATA2, JAK2
11MP:000538511.0CEBPA, DNMT3A, ETV6, GATA2, IDH2, KIT
12MP:000539711.0CEBPA, ETV6, FLT3, GATA2, IDH1, JAK2
13MP:001077110.9CEBPA, CHIC2, ETV6, JAK2, KIT, KRAS
14MP:000301210.9CEBPA, DNMT3A, ETV6, FLT3, KIT, KRAS
15MP:000537010.6CEBPA, GATA2, JAK2, KIT, KRAS, NPM1

Drugs & Therapeutics for Leukemia, Acute Myeloid

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Leukine16 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
FDA Label: -
Disease/s that Drug Treats:transplantation/ replenishment of white blood cells, fungal infections
Indications and Usage:16 -
DrugBank Targets:14 1. Granulocyte-macrophage colony-stimulating factor receptor subunit alpha;2. Interleukin-3 receptor subunit alpha;3. Cytokine receptor common subunit beta;4. Syndecan-2;5. Bone marrow proteoglycan
Mechanism of Action:16 
Target: -
Action: -
FDA: -
2
Lynparza16 44 OLAPARIB AstraZeneca December 2014
FDA Label: Lynparza
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:16 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:14 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:16 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
3
Mylotarg16 44 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
FDA Label: Mylotarg
Disease/s that Drug Treats:Acute Myeloid Leukemia (AML)
Indications and Usage:16 Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia infirst relapse who are 60 years of age or older and who are not considered candidates for othercytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performancestatus and organ dysfunction has not been established.The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). Thereare no controlled trials demonstrating a clinical benefit, such as improvement in disease-relatedsymptoms or increased survival, compared to any other treatment.
DrugBank Targets:14 1. Myeloid cell surface antigen CD33;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: CD33 antigen expressed byhematopoietic cells
Action: binds to form complex that then causes a break in the DNA double strand
FDA: Mylotarg is directed against the CD33 antigen expressed byhematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33antigen results in the formation of a complex that is internalized. Upon internalization, thecalicheamicin derivative is released inside the lysosomes of the myeloid cell. The releasedcalicheamicin derivative binds to DNA in the minor groove resulting in DNA double strandbreaks and cell death.Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adultleukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads tosubstantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cellsare spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumoreffects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.
4
Neupogen16 44 FILGRASTIM Amgen Approval April 1998
FDA Label: Neupogen
Disease/s that Drug Treats:slow white blood cell recovery following chemotherapy
Indications and Usage:16 NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚in patients with nonmyeloid malignancies receiving myelosuppressive anticancerdrugs associated with a significant incidence of severe neutropeniawith fever (1.1) Reduce the time to neutrophil recovery and the duration of fever, followinginduction or consolidation chemotherapy treatment of patients with acutemyeloid leukemia (AML) (1.2) Reduce the duration of neutropenia and neutropenia-related clinicalsequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloidmalignancies undergoing myeloablative chemotherapy followed by bonemarrow transplantation (BMT) (1.3) Mobilize autologous hematopoietic progenitor cells into the peripheralblood for collection by leukapheresis (1.4) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients withcongenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (1.5) Increase survival in patients acutely exposed to myelosuppressive doses ofradiation (Hematopoietic Syndrome of Acute Radiation Syndrome) (1.6)
DrugBank Targets:14 1. Granulocyte colony-stimulating factor receptor;2. Neutrophil elastase
Mechanism of Action:16 
Target: hematopoietic cells
Action: stimulates proliferation/ regulated production of neutophils
FDA: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cellsurface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functionalactivation.Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes‚fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrowand affects neutrophil progenitor proliferation‚ differentiation, and selected end-cell functions (includingenhanced phagocytic ability‚ priming of the cellular metabolism associated with respiratory burst‚antibody-dependent killing, and the increased expression of some cell surface antigens). G-CSF is notspecies-specific and has been shown to have minimal direct in vivo or in vitro effects on the production oractivity of hematopoietic cell types other than the neutrophil lineage.

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 651)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AmsacrineapprovedPhase 4, Phase 3, Phase 1, Phase 2851264-14-32179
Synonyms:
4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide
4'-(9-Acridinylamino)methanesulfon-m-anisidide
4'-(9-Acridinylamino)methanesulfon-meta-anisidide
4'-(9-Acridinylamino)methanesulphon-m-anisidide
5-22-11-00030 (Beilstein Handbook Reference)
51264-14-3
AB1004823
AC1L1D3L
AMSA P-D
Acridinyl Anisidide
Acridinyl anisidide
Acridinylanisidide
Amecrin
Amekrin
Amsacrina
Amsacrina [INN-Spanish]
Amsacrine
Amsacrine (USAN/INN)
Amsacrine [USAN:BAN:INN]
Amsacrinum
Amsacrinum [INN-Latin]
Amsidine
Amsidyl
Amsidyl (TN)
Amsine
BRN 0500176
C01553
C21H19N3O3S
CCRIS 1027
CHEBI:2687
CHEMBL43
CI 880
CI-880
CID2179
Cain's Acridine
D02321
DB00276
EINECS 257-094-3
HSDB 7087
 
I14-9555
LS-1319
Lamasine
Lopac-A-9809
Lopac0_000154
M-AMSA
MAMSA
N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide
N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide
N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide
N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide
N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide
NCGC00015113-01
NCGC00015113-03
NCGC00162077-01
NCI-249992
NCI60_001995
NCIMech_000607
NSC 156303
NSC 249992
NSC-141549
NSC-156303
NSC-249992
NSC249992
Neuro_000118
SN 21429
SN-11841
SN11841
UNII-00DPD30SOY
WLN: T C666 BNJ IMR BO1 DMSW1
amsacrine
m-AMSA
mAMSA
meta-AMSA
meta-Amsacrine
nAMSA
nchem.981-comp12
nchembio.100-comp16
2
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 140585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
3
Arsenic trioxideapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 11221327-53-3518740
Synonyms:
28380-38-3
AC1L24QX
AI3-01163
Acide Arsenieux
Acide Arsenieux [French]
Acide arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Anhydride arsenieux [French]
Arseneous anhydride
Arseneous oxide
Arseni Trioxydum
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic Oxidearsenous Trioxide
Arsenic Sesquioxide
Arsenic Trioxide [UN1561] [Poison]
Arsenic blanc [French]
Arsenic oxide
Arsenic oxide (As2O3)
Arsenic sesquioxide
Arsenic trioxide (JP15/USAN)
Arsenic trioxide [JAN]
Arsenic trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic(III) trioxide
Arsenic, White
Arsenicum Album
Arsenicum album
Arsenigen Saure
Arsenigen Saure [German]
Arsenigen saure [German]
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious Trioxide
Arsenious trioxide
Arsenite
Arsenolite
Arsenous Acid
 
Arsenous Acid Anhydride
Arsenous Anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsenous oxide [ISO]
Arsenox
Arsentrioxide
Arsodent
C006632
CCRIS 5455
CHEMBL405991
CID14888
Caswell No. 059
Claudelite
Claudetite
Crude Arsenic
D02106
Di-Arsenic Trioxide
Diarsenic Trioxide
Diarsenic trioxide
Diarsonic Trioxide
EINECS 215-481-4
EPA Pesticide Chemical Code 007001
HSDB 419
LS-761
MolPort-006-823-587
Oxyde Arsenieux
Oxyde Arsenieux [ISO-French]
Poison Flour
RCRA waste no. P012
Rcra waste number P012
Tetraarsenic hexaoxide
Trisenox
Trisenox (TN)
Trixenox
UN 1561
UN1561
UNII-S7V92P67HO
White Arsenic
White arsenic
arsenic trioxide
arsenic(3+)
naonobin
oxygen(2-)
4
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
5
Decitabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 12442353-33-5451668
Synonyms:
-Deoxycytidine
-azacytidine
2'-Deoxy-5-azacytidine
2353-33-5
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5-AZAdC
5-Aza-2&prime
5-Aza-2'-deoxycytidine
5-Azadeoxycytidine
5-Deoxy-2&prime
5-aza-2'-deoxycytidine
5-aza-2-deoxycytidine
5-aza-CdR
5-aza-dC
5A2dc
A3656_SIGMA
AC-1135
AC1L9PS9
AzadC
 
Azadc
CHEBI:50131
CHEMBL1201129
CID451668
D03665
DB01262
Dacogen
Dacogen (TN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
Decitabine
Decitabine (USAN/INN)
Dezocitidine
E-7373
FT-0082622
MLS001332587
MLS001332588
MolMap_000063
NCGC_5ADOC
NSC-127716
NSC127716
S1200_Selleck
SBB066121
SMR000857076
TL8001944
6
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1126933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
7
Histamineapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
8
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
9
ThiotepaapprovedPhase 4, Phase 3, Phase 2, Phase 122652-24-45453
Synonyms:
 
Thioplex
10
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 115511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
11
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
12
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
13
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
14
Azacitidineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1529320-67-29444
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 AZC
5 Azacytidine
5-AC
5-AZAC
5-AZCR
5-Azacytidine
5-aza-CR
5-azacitidine
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5AzaC
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
 
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
LS-1189
Ladakamycin
Lopac0_000035
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC-102816
NSC102816
Pharmion Brand of Azacitidine
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
SPECTRUM1502111
ST056940
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
Spectrum_001262
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
WR-183027
ZINC03861768
cMAP_000082
mylo sar
pyrimidine antimetabolite: inhibits nucleic acid replication
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
wr 183027
15
Topotecanapproved, investigationalPhase 4, Phase 2, Phase 1349119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
16
Cytarabineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11117147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine (JP15/USP/INN)
Cytarabine [USAN:INN:BAN:JAN]
 
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
17
FludarabineapprovedPhase 4, Phase 2, Phase 3, Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
18
IdarubicinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121458957-92-942890
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4-DMD
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
I 1656
I06-1097
I1656_SIGMA
IDARUBICIN
 
IMI 30
IMI-30
Idamycin
Idamycin PFS
Idarubicin (INN)
Idarubicin Aglycone
Idarubicin HCl PFS
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin Hydrochloride
Idarubicin [INN:BAN]
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
KBioSS_002388
LS-94015
Lopac0_000600
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC-256439
NSC256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
idarubicin hydrochloride
19
VidarabineapprovedPhase 4, Phase 3, Phase 2, Phase 152124356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
20
LenalidomideapprovedPhase 4, Phase 3, Phase 2, Phase 1736191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide
21
DaunorubicinapprovedPhase 4, Phase 3, Phase 2, Phase 127320830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
22
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
23
Mitoxantroneapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 127265271-80-94212
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
AN-584/42007670
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
IDI1_000516
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
LS-20638
Liposome Encapsulated Mitoxantrone (LEM)
Lopac-M-6545
Lopac0_000779
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MIX
 
MLS002703044
Misostol
Misostol (TN)
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
Mitoxantrone
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantrone 2HCl
Mitoxantrone HCl
Mitoxantrone [INN]
Mitoxantrone dihydrochloride
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NCI60_002276
NCI60_002535
NChemBio.2007.10-comp17
NINDS_000516
NSC 279836
NSC-279836
NSC-287836
NSC-299195
NSC-301739
NSC-301739D
NSC279836
NSC299195
NSC301739
Neuro_000153
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
SR-01000076001
SR-01000076001-7
STK631833
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
Spectrum_001655
UNII-BZ114NVM5P
VU0244399-2
mitoxantrone
24
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1700284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
25
Posaconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 156171228-49-2147912
Synonyms:
1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
171228-49-2
177571-33-4
4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
AC-1350
AC1L3W34
AC1LAHLQ
AKOS005145917
CHEBI:434337
CHEMBL1397
CHEMBL371938
CHEMBL371939
CID10532764
CID11520437
CID11542142
CID147912
CID468595
D02555
 
DB01263
HSDB 7421
LS-186118
LS-186988
LS-187630
MolPort-006-666-426
Noxafil
Noxafil (TN)
Noxafil, Posaconazole
Posaconazole
Posaconazole (USAN/INN)
Posaconazole SP
Posaconazole [USAN:INN:BAN]
Posaconazole in combination with MGCD290
S1257_Selleck
SCH-56592
SCH56592
Sch 56592
Spriafil
UNII-6TK1G07BHZ
X2N
posaconazole
26
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
27
Micafunginapproved, investigationalPhase 4, Phase 258235114-32-63081921, 477468
Synonyms:
5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate
5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
AC-6107
AC1L9WY8
AC1MIXSV
CHEBI:600520
CHEMBL1201351
CID11804463
CID3081921
CID477468
 
CID6602291
DB01141
FK-463
FK463
I14-11710
LS-184079
LS-187369
Micafungin
Mycamine
Mycamine(TM)
UNII-R10H71BSWG
28
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
29
Tretinoinapproved, investigational, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1228302-79-45538
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-trans Retinoic Acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
30
Vitamin Capproved, nutraceuticalPhase 4, Phase 2, Phase 153150-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
 
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
31
Nicotinamideapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 191998-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3 amide
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
32
Niacinapproved, investigational, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 192359-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Nicacid
Nicamin
Nicangin
 
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
33
AclarubicininvestigationalPhase 4, Phase 2, Phase 1557576-44-0451415
Synonyms:
.alpha.-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester
10-epi-Aclacinomycin A
57576-44-0
64520-15-6
72711-48-9
77448-81-8
79617-46-2
A8959_SIGMA
AC1L1CQ0
AC1L27WP
AC1L48VL
AC1L4DB3
AC1L7CAE
AC1L9PMJ
AC1O8MK9
AC1O8OA8
Aclacin
Aclacinomycin A
Aclacur
Aclarubicin (USAN/INN)
Aclarubicin [USAN:BAN:INN]
Aclarubicine
Aclarubicine [INN-French]
Aclarubicino
Aclarubicino [INN-Spanish]
Aclarubicinum
Aclarubicinum [INN-Latin]
Aclucinomycin A
Antibiotic MA 144A
Antibiotic MA 144A1
Antibiotic MA 144G1
Antibiotic MA144-A1
BCBcMAP01_000191
C42H53NO15
CCRIS 2262
CHEBI:170281
CHEMBL45414
CHEMBL502620
CID152688
CID154943
CID2008
CID308141
CID42474
CID451415
 
CID6712061
CID6713097
D02756
DivK1c_000678
EINECS 260-824-3
HMS2089B13
HMS502B20
IDI1_000678
Jaclacin
KBio1_000678
KBio2_000947
KBio2_003515
KBio2_006083
KBioGR_001156
KBioSS_000947
LS-93909
LS-93943
LS-93950
MA 144-A1
MA 144G1
MA-144A1
MolPort-003-665-565
MolPort-003-983-841
MolPort-004-845-383
NCI60_001746
NCI60_018879
NCIMech_000395
NINDS_000678
NSC 208734
NSC-208,734
NSC-208734
NSC208734
NSC240619
Neuro_000108
QTL1_000003
SMP1_000003
SPBio_001967
STK177207
Spectrum2_001934
Spectrum4_000768
Spectrum5_001041
Spectrum_000467
UNII-74KXF8I502
acene-1-carboxylate
aclarubicin
34Trace ElementsPhase 4, Phase 3, Phase 1, Phase 26001
35Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
36Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111226
37MicronutrientsPhase 4, Phase 3, Phase 1, Phase 26001
38Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
39Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14337
40Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 13689
41interferonsPhase 4, Phase 2, Phase 12175
42BB 1101Phase 4, Phase 3, Phase 2, Phase 12171
43Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15592
44Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 2, Phase 12171
45Dexamethasone acetatePhase 4, Phase 3, Phase 2, Phase 121711177-87-3
46Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
47AntioxidantsPhase 4, Phase 3, Phase 1, Phase 23050
48Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110729
496-MercaptopurinePhase 4, Phase 3, Phase 2, Phase 1202
50Interferon-alphaPhase 4, Phase 2, Phase 11152

Interventional clinical trials:

(show top 50)    (show all 2533)
idNameStatusNCT IDPhase
1Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid LeukaemiaUnknown statusNCT02277847Phase 4
2AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine ChemotherapyUnknown statusNCT02024308Phase 4
33 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid LeukemiaUnknown statusNCT01587430Phase 4
4Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationUnknown statusNCT01806116Phase 4
5Efficacy of G-CSF-Priming in Elderly AML PatientsUnknown statusNCT00199147Phase 4
6Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionUnknown statusNCT01901666Phase 4
7AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic LeukemiaUnknown statusNCT00180128Phase 4
8Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With ArsenicUnknown statusNCT00196768Phase 4
9Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
10LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
11AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 YearsCompletedNCT00180102Phase 4
12Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
13Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid LeukemiaCompletedNCT01347996Phase 4
14AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia PatientsCompletedNCT00180115Phase 4
15Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715Phase 4
16SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
17Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraCCompletedNCT00180167Phase 4
18Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual CareCompletedNCT00161668Phase 4
19Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
20Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)CompletedNCT00686543Phase 4
21A Study for Dacogen Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01041846Phase 4
22Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
23Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
24Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)CompletedNCT00465933Phase 4
25Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)CompletedNCT00408278Phase 4
26Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)CompletedNCT00504764Phase 4
27Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLRecruitingNCT02474290Phase 4
28Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML PatientsRecruitingNCT03150134Phase 4
29Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLRecruitingNCT02926586Phase 4
30Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCTRecruitingNCT02027064Phase 4
31Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsRecruitingNCT02267993Phase 4
32Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal InfectionsRecruitingNCT02805946Phase 4
33Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic LeukemiaRecruitingNCT02618109Phase 4
34A Rollover Study to Provide Continued Treatment With EltrombopagRecruitingNCT01957176Phase 4
35Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APLRecruitingNCT01987297Phase 4
36Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related AplasiaActive, not recruitingNCT01819792Phase 4
37Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)Active, not recruitingNCT03026842Phase 4
38Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT01200355Phase 4
39A Study for Improving the Outcome of Childhood Acute Promyeloid LeukemiaEnrolling by invitationNCT02200978Phase 4
40Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and ControlsNot yet recruitingNCT02809222Phase 4
41King's Invasive Aspergillosis Study IINot yet recruitingNCT02875743Phase 4
42G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorNot yet recruitingNCT02933333Phase 4
43A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTNot yet recruitingNCT03176849Phase 4
44Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Not yet recruitingNCT01339988Phase 4
45LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)TerminatedNCT01198054Phase 4
46the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia PatientUnknown statusNCT01766375Phase 3
47A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaUnknown statusNCT01303796Phase 3
48Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsUnknown statusNCT01633099Phase 3
49Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid LeukaemiaUnknown statusNCT00224614Phase 3
50Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid LeukemiaUnknown statusNCT00002658Phase 3

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Genetic Tests for Leukemia, Acute Myeloid

About this section

Genetic tests related to Leukemia, Acute Myeloid:

id Genetic test Affiliating Genes
1 Acute Myeloid Leukemia27 24 ARHGEF12, CBFB, CHEK2, ETV6, FLT3, GATA2, GMPS, IDH1, IDH2, JAK2 (show all 22)

KIT, LPP, MLF1, NPM1, NRAS, NSD1, NSD3, NUP214, PICALM, RUNX1, TERT, WT1

2 Leukemia, Acute Myeloid, Susceptibility to27
3 Leukemia, Acute Myelogenous24 KRAS

Anatomical Context for Leukemia, Acute Myeloid

About this section

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

36
Myeloid, Bone, Bone marrow, Neutrophil, Testes, Monocytes, Skin

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowCommon Myeloid Progenitor Cells Affected by disease
2 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

About this section

Articles related to Leukemia, Acute Myeloid:

idTitleAuthorsYear
1
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. (27987385)
2016
2
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. (21463117)
2011
3
Concomitant chronic lymphocytic leukemia, acute myeloid leukemia, and thrombosis with protein C deficiency. Case report and review of the literature. (2646007)
1989

Variations for Leukemia, Acute Myeloid

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

70
id Symbol AA change Variation ID SNP ID
1CEBPAp.His84LeuVAR_072677rs28931590
2JAK2p.Lys607AsnVAR_032696rs121912472
3JAK2p.Val617PheVAR_032697rs77375493
4SETBP1p.Gly870SerVAR_063809rs267607040
5SETBP1p.Ser854AlaVAR_069848
6SETBP1p.Gly870ArgVAR_069854
7SETBP1p.Ile871SerVAR_069856

Clinvar genetic disease variations for Leukemia, Acute Myeloid:

5 (show all 209)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
3TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
4KRASNM_ 033360.3(KRAS): c.38G> A (p.Gly13Asp)SNVPathogenic/ Likely pathogenicrs112445441GRCh37Chr 12, 25398281: 25398281
5KRASNM_ 004985.4(KRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
6KRASNM_ 004985.4(KRAS): c.35G> T (p.Gly12Val)SNVPathogenic/ Likely pathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
7KRASNM_ 004985.4(KRAS): c.27_ 29dupTGG (p.Gly10_ Ala11insGly)duplicationPathogenicrs606231202GRCh38Chr 12, 25245356: 25245358
8HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
9HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
10HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
11HRASNM_ 005343.3(HRAS): c.436G> A (p.Ala146Thr)SNVPathogenic/ Likely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
12HRASNM_ 005343.3(HRAS): c.437C> T (p.Ala146Val)SNVPathogenic/ Likely pathogenicrs121917759GRCh37Chr 11, 533466: 533466
13HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
14TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
15TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
16KITNM_ 000222.2(KIT): c.2447A> T (p.Asp816Val)SNVPathogenic/ Likely pathogenicrs121913507GRCh37Chr 4, 55599321: 55599321
17KITNM_ 000222.2(KIT): c.2446G> T (p.Asp816Tyr)SNVPathogenic/ Likely pathogenicrs121913506GRCh37Chr 4, 55599320: 55599320
18KITNM_ 000222.2(KIT): c.2446G> C (p.Asp816His)SNVPathogenic/ Likely pathogenicrs121913506GRCh37Chr 4, 55599320: 55599320
19NRASNM_ 002524.4(NRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs121434595GRCh37Chr 1, 115258745: 115258745
20NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
21NRASNM_ 002524.4(NRAS): c.38G> A (p.Gly13Asp)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
22NPM1NM_ 002520.6(NPM1): c.860_ 863dupTCTG (p.Trp288Cysfs)duplicationPathogenicrs587776806GRCh38Chr 5, 171410540: 171410543
23NPM1NM_ 002520.6(NPM1): c.863_ 864insCATG (p.Trp288Cysfs)insertionPathogenicrs587776806GRCh38Chr 5, 171410543: 171410544
24NPM1NM_ 002520.6(NPM1): c.863_ 864insCGTG (p.Trp288Cysfs)insertionPathogenicrs587776806GRCh38Chr 5, 171410543: 171410544
25NPM1NM_ 002520.6(NPM1): c.863_ 864insCCTG (p.Trp288Cysfs)insertionPathogenicrs587776806GRCh38Chr 5, 171410543: 171410544
26TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
27JAK2NM_ 004972.3(JAK2): c.1849G> T (p.Val617Phe)SNVPathogenic/ Likely pathogenic, risk factorrs77375493GRCh37Chr 9, 5073770: 5073770
28JAK2NM_ 004972.3(JAK2): c.1821G> C (p.Lys607Asn)SNVPathogenicrs121912472GRCh37Chr 9, 5073742: 5073742
29IDH2NM_ 002168.3(IDH2): c.419G> A (p.Arg140Gln)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
30IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
31FLT3NM_ 004119.2(FLT3): c.2520_ 2521insGGATCC (p.Ser840_ Asn841insGlySer)insertionPathogenicrs398122514GRCh37Chr 13, 28592624: 28592625
32FLT3NM_ 004119.2(FLT3): c.2504A> T (p.Asp835Val)SNVPathogenicrs121909646GRCh37Chr 13, 28592641: 28592641
33FLT3NM_ 004119.2(FLT3): c.2503G> C (p.Asp835His)SNVPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
34FLT3NM_ 004119.2(FLT3): c.2503G> A (p.Asp835Asn)SNVPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
35FLT3FLT3, ASP835GLUundetermined variantPathogenic
36FLT3NM_ 004119.2(FLT3): c.2503G> T (p.Asp835Tyr)SNVPathogenicrs121913488GRCh37Chr 13, 28592642: 28592642
37FLT3NM_ 004119.2(FLT3): c.2503_ 2505delGAT (p.Asp835del)deletionPathogenic/ Likely pathogenicrs121913486GRCh37Chr 13, 28592640: 28592642
38CEBPANM_ 004364.4(CEBPA): c.115_ 121delCCCGCGC (p.Pro39Serfs)deletionPathogenicrs587776848GRCh38Chr 19, 33302294: 33302300
39CEBPANM_ 004364.4(CEBPA): c.148G> T (p.Glu50Ter)SNVPathogenicrs121912791GRCh37Chr 19, 33793173: 33793173
40CEBPANM_ 004364.4(CEBPA): c.251A> T (p.His84Leu)SNVPathogenicrs28931590GRCh37Chr 19, 33793070: 33793070
41CEBPANM_ 004364.4(CEBPA)duplicationPathogenicGRCh38Chr 19, 33301424: 33301480
42CEBPANM_ 004364.4(CEBPA): c.925_ 951dup27 (p.Leu317_ Thr318insGluThrGlnGlnLysValLeuGluLeu)duplicationPathogenicGRCh38Chr 19, 33301464: 33301490
43CEBPANM_ 004364.4(CEBPA): c.211_ 214dupGCCG (p.Ala72Glyfs)duplicationPathogenicrs587776849GRCh38Chr 19, 33302201: 33302204
44CEBPANM_ 004364.4(CEBPA): c.68delC (p.Pro23Argfs)deletionPathogenicrs137852728GRCh38Chr 19, 33302347: 33302347
45PTPN11NM_ 002834.4(PTPN11): c.214G> A (p.Ala72Thr)SNVLikely pathogenicrs121918453GRCh38Chr 12, 112450394: 112450394
46NRASNM_ 002524.4(NRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
47KRASNM_ 004985.4(KRAS): c.183A> C (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
48HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
49TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
50TP53NM_ 000546.5(TP53): c.578A> T (p.His193Leu)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
51ATG2BNC_ 000014.9: g.95696766_ 96390792dup694027duplicationLikely pathogenicGRCh37Chr 14, 96163103: 96857129
52CSF3RNM_ 156039.3(CSF3R): c.1853C> T (p.Thr618Ile)SNVPathogenic/ Likely pathogenicrs796065343GRCh37Chr 1, 36933434: 36933434
53DDX41NM_ 016222.3(DDX41): c.415_ 418dupGATG (p.Asp140Glyfs)duplicationPathogenic, risk factorrs762890562GRCh37Chr 5, 176942946: 176942949
54TERTNM_ 198253.2(TERT): c.1620C> G (p.Ile540Met)SNVLikely pathogenicrs797046041GRCh38Chr 5, 1282578: 1282578
55CEBPANM_ 004364.4(CEBPA): c.141delC (p.Ala48Profs)deletionPathogenicrs137852730GRCh37Chr 19, 33793180: 33793180
56CEBPANM_ 004364.4(CEBPA): c.198_ 201dupCTAC (p.Ile68Leufs*41)duplicationPathogenicrs137852731GRCh37Chr 19, 33793120: 33793123
57CEBPANM_ 004364.4(CEBPA): c.217_ 218insC (p.Phe73Serfs)insertionPathogenicrs137852733GRCh37Chr 19, 33793103: 33793104
58CEBPANM_ 004364.4(CEBPA): c.318_ 319dupTG (p.Asp107Valfs*54)duplicationPathogenicrs137852732GRCh37Chr 19, 33793002: 33793003
59CEBPANM_ 004364.4(CEBPA): c.68dupC (p.His24Alafs)duplicationPathogenicrs137852729GRCh37Chr 19, 33793253: 33793253
60TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
61NRASNM_ 002524.4(NRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs121913237GRCh38Chr 1, 114716126: 114716126
62SF3B1NM_ 012433.3(SF3B1): c.1998G> T (p.Lys666Asn)SNVPathogenic/ Likely pathogenicrs377023736GRCh37Chr 2, 198267359: 198267359
63TP53NM_ 000546.5(TP53): c.743G> T (p.Arg248Leu)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
64TP53NM_ 000546.5(TP53): c.577C> T (p.His193Tyr)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
65TP53NM_ 000546.5(TP53): c.818G> C (p.Arg273Pro)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
66TP53NM_ 000546.5(TP53): c.743G> C (p.Arg248Pro)SNVLikely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
67TP53NM_ 000546.5(TP53): c.643A> G (p.Ser215Gly)SNVLikely pathogenicrs886039484GRCh37Chr 17, 7578206: 7578206
68NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
69GATA2NM_ 001145661.1(GATA2): c.1192C> T (p.Arg398Trp)SNVPathogenic/ Likely pathogenicrs387906629GRCh37Chr 3, 128200113: 128200113
70GATA2NM_ 001145661.1(GATA2): c.1061C> T (p.Thr354Met)SNVPathogenic/ Likely pathogenic, risk factorrs387906631GRCh37Chr 3, 128200744: 128200744
71TGM6NM_ 198994.2(TGM6): c.1550T> G (p.Leu517Trp)SNVPathogenicrs387907097GRCh37Chr 20, 2398091: 2398091
72HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
73NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
74NRASNM_ 002524.4(NRAS): c.183A> C (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
75NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
76NRASNM_ 002524.4(NRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs121434596GRCh37Chr 1, 115258744: 115258744
77DNMT3ANM_ 175629.2(DNMT3A): c.2645G> T (p.Arg882Leu)SNVPathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
78DNMT3ANM_ 175629.2(DNMT3A): c.2645G> C (p.Arg882Pro)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
79DNMT3ANM_ 175629.2(DNMT3A): c.2645G> A (p.Arg882His)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
80DNMT3ANM_ 175629.2(DNMT3A): c.2644C> T (p.Arg882Cys)SNVPathogenic/ Likely pathogenicrs377577594GRCh37Chr 2, 25457243: 25457243
81DNMT3ANM_ 022552.4(DNMT3A): c.2644C> G (p.Arg882Gly)SNVPathogenicrs377577594GRCh37Chr 2, 25457243: 25457243
82DNMT3ANM_ 022552.4(DNMT3A): c.2644C> A (p.Arg882Ser)SNVPathogenicrs377577594GRCh37Chr 2, 25457243: 25457243
83IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
84IDH1NM_ 001282386.1(IDH1): c.395G> C (p.Arg132Pro)SNVPathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
85IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
86IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
87IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
88KITNM_ 000222.2(KIT): c.2446_ 2447delGAinsAT (p.Asp816Ile)indelPathogenicrs1057519709GRCh37Chr 4, 55599320: 55599321
89KITNM_ 000222.2(KIT): c.2466T> A (p.Asn822Lys)SNVPathogenic/ Likely pathogenicrs121913514GRCh37Chr 4, 55599340: 55599340
90KITNM_ 000222.2(KIT): c.2466T> G (p.Asn822Lys)SNVPathogenic/ Likely pathogenicrs121913514GRCh37Chr 4, 55599340: 55599340
91FLT3NM_ 004119.2(FLT3): c.2508C> G (p.Ile836Met)SNVPathogenicrs121913232GRCh37Chr 13, 28592637: 28592637
92FLT3NM_ 004119.2(FLT3): c.2506A> C (p.Ile836Leu)SNVPathogenicrs1057519726GRCh37Chr 13, 28592639: 28592639
93FLT3NM_ 004119.2(FLT3): c.2505T> G (p.Asp835Glu)SNVPathogenicrs121913487GRCh37Chr 13, 28592640: 28592640
94FLT3NM_ 004119.2(FLT3): c.2505T> A (p.Asp835Glu)SNVPathogenicrs121913487GRCh37Chr 13, 28592640: 28592640
95FLT3NM_ 004119.2(FLT3): c.2504A> C (p.Asp835Ala)SNVPathogenicrs121909646GRCh37Chr 13, 28592641: 28592641
96IDH2NM_ 002168.3(IDH2): c.516G> C (p.Arg172Ser)SNVPathogenicrs1057519736GRCh37Chr 15, 90631837: 90631837
97IDH2NM_ 001289910.1(IDH2): c.359G> T (p.Arg120Met)SNVPathogenic/ Likely pathogenicrs121913503GRCh37Chr 15, 90631838: 90631838
98IDH2NM_ 001289910.1(IDH2): c.359G> A (p.Arg120Lys)SNVPathogenic/ Likely pathogenicrs121913503GRCh37Chr 15, 90631838: 90631838
99IDH2NM_ 002168.3(IDH2): c.419G> T (p.Arg140Leu)SNVPathogenic/ Likely pathogenicrs121913502GRCh37Chr 15, 90631934: 90631934
100IDH2NM_ 002168.3(IDH2): c.418C> T (p.Arg140Trp)SNVPathogenic/ Likely pathogenicrs267606870GRCh37Chr 15, 90631935: 90631935
101SF3B1NM_ 012433.3(SF3B1): c.2098A> G (p.Lys700Glu)SNVLikely pathogenicrs559063155GRCh37Chr 2, 198266834: 198266834
102SF3B1NM_ 012433.3(SF3B1): c.1998G> C (p.Lys666Asn)SNVLikely pathogenicrs377023736GRCh37Chr 2, 198267359: 198267359
103SF3B1NM_ 012433.3(SF3B1): c.1997A> G (p.Lys666Arg)SNVLikely pathogenicrs374250186GRCh37Chr 2, 198267360: 198267360
104SF3B1NM_ 012433.3(SF3B1): c.1997A> C (p.Lys666Thr)SNVLikely pathogenicrs374250186GRCh37Chr 2, 198267360: 198267360
105SF3B1NM_ 012433.3(SF3B1): c.1996A> G (p.Lys666Glu)SNVLikely pathogenicrs754688962GRCh37Chr 2, 198267361: 198267361
106NPM1NM_ 002520.6(NPM1): c.862_ 863insCATG (p.Trp288Serfs)insertionLikely pathogenicrs1057519744GRCh37Chr 5, 170837546: 170837547
107NPM1NM_ 002520.6(NPM1): c.862_ 863insCCTG (p.Trp288Serfs)insertionLikely pathogenicrs1057519744GRCh37Chr 5, 170837546: 170837547
108NPM1NM_ 002520.6(NPM1): c.862_ 863insTCAG (p.Trp288Phefs)insertionLikely pathogenicrs1057519744GRCh37Chr 5, 170837546: 170837547
109NPM1NM_ 002520.6(NPM1): c.862_ 863insTCTG (p.Trp288Phefs)insertionLikely pathogenicrs1057519744GRCh37Chr 5, 170837546: 170837547
110WT1NM_ 001198551.1(WT1): c.506_ 507insTGTACGGT (p.Ala170Valfs)insertionLikely pathogenicrs1057519745GRCh37Chr 11, 32417909: 32417910
111FLT3NM_ 004119.2(FLT3): c.2516A> G (p.Asp839Gly)SNVLikely pathogenicrs991132188GRCh37Chr 13, 28592629: 28592629
112TP53NM_ 001126112.2(TP53): c.746G> C (p.Arg249Thr)SNVLikely pathogenicrs587782329GRCh37Chr 17, 7577535: 7577535
113TP53NM_ 001126112.2(TP53): c.518T> G (p.Val173Gly)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
114TP53NM_ 001126113.2(TP53): c.518T> C (p.Val173Ala)SNVLikely pathogenicrs1057519747GRCh37Chr 17, 7578412: 7578412
115RUNX1NM_ 001754.4(RUNX1): c.601C> T (p.Arg201Ter)SNVLikely pathogenicrs1057519748GRCh37Chr 21, 36231783: 36231783
116RUNX1NM_ 001754.4(RUNX1): c.486G> T (p.Arg162Ser)SNVLikely pathogenicrs1057519749GRCh37Chr 21, 36252876: 36252876
117RUNX1NM_ 001754.4(RUNX1): c.486G> C (p.Arg162Ser)SNVLikely pathogenicrs1057519749GRCh37Chr 21, 36252876: 36252876
118RUNX1NM_ 001754.4(RUNX1): c.485G> A (p.Arg162Lys)SNVLikely pathogenicrs1057519750GRCh37Chr 21, 36252877: 36252877
119RUNX1NM_ 001754.4(RUNX1): c.484A> G (p.Arg162Gly)SNVLikely pathogenicrs1057519751GRCh38Chr 21, 34880581: 34880581
120U2AF1NM_ 001025203.1(U2AF1): c.470A> G (p.Gln157Arg)SNVLikely pathogenicrs371246226GRCh37Chr 21, 44514777: 44514777
121U2AF1NM_ 001025203.1(U2AF1): c.470A> C (p.Gln157Pro)SNVLikely pathogenicrs371246226GRCh37Chr 21, 44514777: 44514777
122U2AF1NM_ 006758.2(U2AF1): c.101C> T (p.Ser34Phe)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
123U2AF1NM_ 001025203.1(U2AF1): c.101C> A (p.Ser34Tyr)SNVLikely pathogenicrs371769427GRCh37Chr 21, 44524456: 44524456
124JAK1NM_ 002227.3(JAK1): c.1972G> T (p.Val658Phe)SNVLikely pathogenicrs1057519753GRCh37Chr 1, 65312347: 65312347
125HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> T (p.Gln61Leu)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
126SF3B1NM_ 012433.3(SF3B1): c.2100A> T (p.Lys700Asn)SNVLikely pathogenicrs1057519755GRCh37Chr 2, 198266832: 198266832
127SF3B1NM_ 012433.3(SF3B1): c.2100A> C (p.Lys700Asn)SNVLikely pathogenicrs1057519755GRCh37Chr 2, 198266832: 198266832
128SF3B1NM_ 012433.3(SF3B1): c.2099A> T (p.Lys700Ile)SNVLikely pathogenicrs1057519756GRCh37Chr 2, 198266833: 198266833
129SF3B1NM_ 012433.3(SF3B1): c.2099A> G (p.Lys700Arg)SNVLikely pathogenicrs1057519756GRCh37Chr 2, 198266833: 198266833
130SF3B1NM_ 012433.3(SF3B1): c.2099A> C (p.Lys700Thr)SNVLikely pathogenicrs1057519756GRCh38Chr 2, 197402109: 197402109
131SF3B1NM_ 012433.3(SF3B1): c.2098A> T (p.Lys700Ter)SNVLikely pathogenicrs559063155GRCh37Chr 2, 198266834: 198266834
132SF3B1NM_ 012433.3(SF3B1): c.2098A> C (p.Lys700Gln)SNVLikely pathogenicrs559063155GRCh37Chr 2, 198266834: 198266834
133FLT3NM_ 004119.2(FLT3): c.2525A> G (p.Tyr842Cys)SNVLikely pathogenicrs376588714GRCh37Chr 13, 28592620: 28592620
134FLT3NM_ 004119.2(FLT3): c.2524T> C (p.Tyr842His)SNVLikely pathogenicrs1057519762GRCh37Chr 13, 28592621: 28592621
135FLT3NM_ 004119.2(FLT3): c.2503_ 2504delGAinsTT (p.Asp835Phe)indelLikely pathogenicrs1057519763GRCh37Chr 13, 28592641: 28592642
136FLT3NM_ 004119.2(FLT3): c.2073T> G (p.Phe691Leu)SNVLikely pathogenicrs1057519764GRCh37Chr 13, 28601359: 28601359
137FLT3NM_ 004119.2(FLT3): c.2073T> A (p.Phe691Leu)SNVLikely pathogenicrs1057519764GRCh37Chr 13, 28601359: 28601359
138FLT3NM_ 004119.2(FLT3): c.2059A> T (p.Ile687Phe)SNVLikely pathogenicrs1057519765GRCh37Chr 13, 28601373: 28601373
139FLT3NM_ 004119.2(FLT3): c.2028C> G (p.Asn676Lys)SNVLikely pathogenicrs1057519766GRCh37Chr 13, 28602340: 28602340
140FLT3NM_ 004119.2(FLT3): c.2028C> A (p.Asn676Lys)SNVLikely pathogenicrs1057519766GRCh37Chr 13, 28602340: 28602340
141FLT3NM_ 004119.2(FLT3): c.2026A> G (p.Asn676Asp)SNVLikely pathogenicrs1057519767GRCh37Chr 13, 28602342: 28602342
142FLT3NM_ 004119.2(FLT3): c.1952A> G (p.Asp651Gly)SNVLikely pathogenicrs1057519768GRCh37Chr 13, 28602416: 28602416
143FLT3NM_ 004119.2(FLT3): c.1855G> T (p.Gly619Cys)SNVLikely pathogenicrs1057519769GRCh37Chr 13, 28608111: 28608111
144HRAS; LRRC56NM_ 005343.3(HRAS): c.182A> C (p.Gln61Pro)SNVLikely pathogenicrs121913233GRCh37Chr 11, 533874: 533874
145FLT3NM_ 004119.2(FLT3): c.2506_ 2508delATC (p.Ile836del)deletionLikely pathogenicrs121913490GRCh37Chr 13, 28592637: 28592639
146FLT3NM_ 004119.2(FLT3): c.1715A> G (p.Tyr572Cys)SNVLikely pathogenicrs121913491GRCh37Chr 13, 28608341: 28608341
147IDH2NM_ 001289910.1(IDH2): c.358A> T (p.Arg120Trp)SNVLikely pathogenicrs1057519906GRCh37Chr 15, 90631839: 90631839
148IDH2NM_ 001289910.1(IDH2): c.358A> G (p.Arg120Gly)SNVLikely pathogenicrs1057519906GRCh37Chr 15, 90631839: 90631839
149HRAS; LRRC56NM_ 005343.3(HRAS): c.436G> C (p.Ala146Pro)SNVLikely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
150HRAS; LRRC56NM_ 005343.3(HRAS): c.38G> C (p.Gly13Ala)SNVLikely pathogenicrs104894226GRCh37Chr 11, 534285: 534285
151HRAS; LRRC56NM_ 005343.3(HRAS): c.181C> G (p.Gln61Glu)SNVLikely pathogenicrs28933406GRCh38Chr 11, 533875: 533875
152PTPN11NM_ 002834.4(PTPN11): c.215C> A (p.Ala72Asp)SNVLikely pathogenicrs121918454GRCh37Chr 12, 112888199: 112888199
153SF3B2NM_ 006842.2(SF3B2): c.2099A> G (p.Glu700Gly)SNVLikely pathogenicrs1057519960GRCh37Chr 11, 65830884: 65830884
154TP53NM_ 001126113.2(TP53): c.421T> C (p.Cys141Arg)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
155TP53NM_ 001126115.1(TP53): c.25T> G (p.Cys9Gly)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
156TP53NM_ 000546.5(TP53): c.421T> A (p.Cys141Ser)SNVLikely pathogenicrs1057519978GRCh37Chr 17, 7578509: 7578509
157TP53NM_ 001126114.2(TP53): c.422G> T (p.Cys141Phe)SNVLikely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
158TP53NM_ 001126114.2(TP53): c.527G> T (p.Cys176Phe)SNVLikely pathogenicrs786202962GRCh37Chr 17, 7578403: 7578403
159TP53NM_ 001126117.1(TP53): c.130T> A (p.Cys44Ser)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
160TP53NM_ 001126117.1(TP53): c.130T> G (p.Cys44Gly)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
161TP53NM_ 001126112.2(TP53): c.528C> G (p.Cys176Trp)SNVLikely pathogenicrs1057519980GRCh37Chr 17, 7578402: 7578402
162TP53NM_ 001126117.1(TP53): c.130T> C (p.Cys44Arg)SNVLikely pathogenicrs967461896GRCh37Chr 17, 7578404: 7578404
163TP53NM_ 001126113.2(TP53): c.857A> G (p.Glu286Gly)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
164TP53NM_ 001126117.1(TP53): c.460G> C (p.Glu154Gln)SNVLikely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
165TP53NM_ 001126117.1(TP53): c.461A> T (p.Glu154Val)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
166TP53NM_ 000546.5(TP53): c.857A> C (p.Glu286Ala)SNVLikely pathogenicrs1057519985GRCh37Chr 17, 7577081: 7577081
167TP53NM_ 001126113.2(TP53): c.536A> G (p.His179Arg)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
168TP53NM_ 001126117.1(TP53): c.141T> G (p.His47Gln)SNVLikely pathogenicrs876660821GRCh37Chr 17, 7578393: 7578393
169TP53NM_ 001126118.1(TP53): c.419A> T (p.His140Leu)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
170TP53NM_ 001126118.1(TP53): c.418C> A (p.His140Asn)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
171TP53NM_ 001126118.1(TP53): c.418C> G (p.His140Asp)SNVLikely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
172TP53NM_ 001126117.1(TP53): c.140A> C (p.His47Pro)SNVLikely pathogenicrs1057519991GRCh37Chr 17, 7578394: 7578394
173TP53NM_ 001126115.1(TP53): c.182A> C (p.His61Pro)SNVLikely pathogenicrs786201838GRCh37Chr 17, 7578271: 7578271
174TP53NM_ 000546.5(TP53): c.577C> G (p.His193Asp)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
175TP53NM_ 001126113.2(TP53): c.577C> A (p.His193Asn)SNVLikely pathogenicrs876658468GRCh37Chr 17, 7578272: 7578272
176TP53NM_ 001126115.1(TP53): c.187A> T (p.Ile63Phe)SNVLikely pathogenicrs942158624GRCh37Chr 17, 7578266: 7578266
177TP53NM_ 001126118.1(TP53): c.467T> A (p.Ile156Asn)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
178TP53NM_ 001126116.1(TP53): c.188T> G (p.Ile63Ser)SNVLikely pathogenicrs760043106GRCh37Chr 17, 7578265: 7578265
179TP53NM_ 001126116.1(TP53): c.189C> G (p.Ile63Met)SNVLikely pathogenicrs1057519994GRCh37Chr 17, 7578264: 7578264
180TP53NM_ 000546.5(TP53): c.742C> G (p.Arg248Gly)SNVLikely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
181TP53NM_ 001126112.2(TP53): c.818G> T (p.Arg273Leu)SNVLikely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
182TP53NM_ 001126112.2(TP53): c.817C> A (p.Arg273Ser)SNVLikely pathogenicrs121913343GRCh37Chr 17, 7577121: 7577121
183TP53NM_ 000546.5(TP53): c.839G> A (p.Arg280Lys)SNVLikely pathogenicrs121912660GRCh37Chr 17, 7577099: 7577099
184TP53NM_ 001126113.2(TP53): c.838A> G (p.Arg280Gly)SNVLikely pathogenicrs753660142GRCh37Chr 17, 7577100: 7577100
185TP53NM_ 001126115.1(TP53): c.248G> T (p.Ser83Ile)SNVLikely pathogenicrs587782177GRCh37Chr 17, 7578205: 7578205
186TP53NM_ 000546.5(TP53): c.644G> A (p.Ser215Asn)SNVLikely pathogenicrs587782177GRCh37Chr 17, 7578205: 7578205
187TP53NM_ 000546.5(TP53): c.373A> C (p.Thr125Pro)SNVLikely pathogenicrs1057520003GRCh37Chr 17, 7579314: 7579314
188TP53NM_ 001126113.2(TP53): c.374C> G (p.Thr125Arg)SNVLikely pathogenicrs786201057GRCh37Chr 17, 7579313: 7579313
189FLT3NM_ 004119.2(FLT3): c.1780T> C (p.Phe594Leu)SNVLikely pathogenicrs1057520021GRCh37Chr 13, 28608276: 28608276
190FLT3NM_ 004119.2(FLT3): c.1736T> C (p.Val579Ala)SNVLikely pathogenicrs1057520022GRCh37Chr 13, 28608320: 28608320
191FLT3NM_ 004119.2(FLT3): c.2507T> G (p.Ile836Ser)SNVLikely pathogenicrs1057520023GRCh37Chr 13, 28592638: 28592638
192FLT3NM_ 004119.2(FLT3): c.2523C> A (p.Asn841Lys)SNVLikely pathogenicrs749281035GRCh37Chr 13, 28592622: 28592622
193FLT3NM_ 004119.2(FLT3): c.1772A> G (p.Tyr591Cys)SNVLikely pathogenicrs1057520024GRCh37Chr 13, 28608284: 28608284
194FLT3NM_ 004119.2(FLT3): c.2506A> G (p.Ile836Val)SNVLikely pathogenicrs1057519726GRCh38Chr 13, 28018502: 28018502
195FLT3NM_ 004119.2(FLT3): c.1775T> C (p.Val592Ala)SNVLikely pathogenicrs1057520025GRCh37Chr 13, 28608281: 28608281
196FLT3NM_ 004119.2(FLT3): c.2506A> T (p.Ile836Phe)SNVLikely pathogenicrs1057519726GRCh37Chr 13, 28592639: 28592639
197FLT3NM_ 004119.2(FLT3): c.2521A> C (p.Asn841His)SNVLikely pathogenicrs772061268GRCh37Chr 13, 28592624: 28592624
198FLT3NM_ 004119.2(FLT3): c.1987A> C (p.Lys663Gln)SNVLikely pathogenicrs1057520026GRCh37Chr 13, 28602381: 28602381
199TEKNM_ 000459.4(TEK): c.2228G> C (p.Gly743Ala)SNVLikely pathogenicrs202131936GRCh37Chr 9, 27204927: 27204927
200FLT3NM_ 004119.2(FLT3): c.1771T> G (p.Tyr591Asp)SNVLikely pathogenicrs1057520043GRCh37Chr 13, 28608285: 28608285
201NRASNM_ 002524.4(NRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
202NRASNM_ 002524.4(NRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
203NRASNM_ 002524.4(NRAS): c.34G> C (p.Gly12Arg)SNVPathogenic/ Likely pathogenicrs121913250GRCh37Chr 1, 115258748: 115258748
204NRASNM_ 002524.4(NRAS): c.35G> T (p.Gly12Val)SNVPathogenic/ Likely pathogenicrs121913237GRCh37Chr 1, 115258747: 115258747
205CEBPANM_ 004364.4(CEBPA): c.186_ 190delCGACA (p.Asp63Glnfs)deletionLikely pathogenicrs1060502121GRCh37Chr 19, 33793131: 33793135
206KRASNM_ 033360.3(KRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
207NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
208ETV6NM_ 001987.4(ETV6): c.226G> T (p.Glu76Ter)SNVPathogenicrs121434637GRCh37Chr 12, 11992136: 11992136
209ETV6NM_ 001987.4(ETV6): c.1307_ 1308insGGG (p.His436delinsGlnGly)insertionPathogenicrs587776710GRCh37Chr 12, 12043928: 12043929

Copy number variations for Leukemia, Acute Myeloid from CNVD:

6 (show top 50)    (show all 491)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11333611124300000InsertionAcute myeloid leukemia
2137591128000000DeletionAcute myeloid leukemia
3147901110122000110569000Gain or lossAcute myeloid leukemia
4174661142902432245422360DuplicationAcute myeloid leukemia
5180961143961000247125000Gain or lossAcute myeloid leukemia
6208261154656757154656845AmplificationAcute myeloid leukemia
7245891182359000182787000LossAcute myeloid leukemia
8260981197094625197094734AmplificationAcute myeloid leukemia
9261001197094796197094905AmplificationAcute myeloid leukemia
10271481204981000205049000Gain or lossAcute myeloid leukemia
11272631206041820206041907AmplificationAcute myeloid leukemia
12278591214500000224100000DeletionAcute myeloid leukemia
13284911222606000222909000Gain or lossAcute myeloid leukemia
14293411230606000230646000Gain or lossAcute myeloid leukemia
153294314068356540683656AmplificationAcute myeloid leukemia
163294414068649440686582AmplificationAcute myeloid leukemia
173308414207200042456000Gain or lossAcute myeloid leukemia
1835033159130007696000Gain or lossAcute myeloid leukemia
193560816529670565296779AmplificationAcute myeloid leukemia
203576916707400069951000Gain or lossAcute myeloid leukemia
213608517130590271305987AmplificationmiR-186Acute myeloid leukemia
22381871016700000InsertionIL15RAAcute myeloid leukemia
23381881016700000InsertionPRKCQAcute myeloid leukemia
243867710104186259104186331DeletionAcute myeloid leukemia
253880410105144000105144148DeletionAcute myeloid leukemia
263914410110889374110889450DeletionAcute myeloid leukemia
273990210122017230122017301Deletionlet-7a-2Acute myeloid leukemia
2841668102189327822027081LossMLLT10Acute myeloid leukemia
2941990102707553027189965TranslateSSH3BP1Acute myeloid leukemia
3043278104610000049900000Copy numberGDF10Acute myeloid leukemia
3144445105716524757165335DeletionAcute myeloid leukemia
3244874116465860964658718DeletionmiR-192Acute myeloid leukemia
33453691070521000135283000GainAcute myeloid leukemia
34476811096486000100815000LossAcute myeloid leukemia
354959211108316750133951370TriplicationAcute myeloid leukemia
365014211114500000121200000Copy numberMLLAcute myeloid leukemia
375019011115400000120700000InsertionDDX6Acute myeloid leukemia
385019111115400000120700000InsertionETS1Acute myeloid leukemia
395019211115400000120700000InsertionFLI1Acute myeloid leukemia
405019311115400000120700000InsertionMLLAcute myeloid leukemia
415026111116297361116448564LossAcute myeloid leukemia
425034611117203762118563610AmplificationAcute myeloid leukemia
435038511117603158117860329DuplicationAcute myeloid leukemia
445043711117820656117856311GainMLLAcute myeloid leukemia
455064011118585028127052111DeletionAcute myeloid leukemia
465146811126537000130235000GainAcute myeloid leukemia
475151211127394408133951311AmplificationAcute myeloid leukemia
48528101120164062019065MethylationH19Acute myeloid leukemia
4953744113240932132457081MutationWT1Acute myeloid leukemia
5054217113967100039746000LossAcute myeloid leukemia

Expression for genes affiliated with Leukemia, Acute Myeloid

About this section
Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for genes affiliated with Leukemia, Acute Myeloid

About this section

GO Terms for genes affiliated with Leukemia, Acute Myeloid

About this section

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleoplasmGO:000565411.7CEBPA, DNMT3A, GATA2, JAK2, MLLT10, NPM1
2focal adhesionGO:000592511.5JAK2, KRAS, LPP, NPM1, NUP214
3nucleusGO:000563411.1CEBPA, DNMT3A, ETV6, FLT3, GATA2, JAK2

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1cytokine-mediated signaling pathwayGO:001922111.4CEBPA, FLT3, JAK2, KIT, KRAS
2hemopoiesisGO:003009711.4FLT3, GATA2, KIT, PICALM, RUNX1
3positive regulation of cell proliferationGO:000828411.4FLT3, JAK2, KIT, KRAS, NPM1
4mitochondrion organizationGO:000700511.3CEBPA, IDH2, TERT
5positive regulation of MAP kinase activityGO:004340611.3FLT3, KIT, KRAS
6positive regulation of phosphatidylinositol 3-kinase signalingGO:001406811.3FLT3, JAK2, KIT
7hematopoietic stem cell proliferationGO:007142511.3ETV6, RUNX1
8positive regulation of tyrosine phosphorylation of STAT proteinGO:004253111.3FLT3, JAK2, KIT
92-oxoglutarate metabolic processGO:000610311.3IDH1, IDH2
10myeloid progenitor cell differentiationGO:000231811.3FLT3, KIT
11glyoxylate cycleGO:000609711.3IDH1, IDH2
12isocitrate metabolic processGO:000610211.3IDH1, IDH2
13negative regulation of glial cell proliferationGO:006025311.3IDH2, TERT
14positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252311.2JAK2, KIT
15positive regulation of vascular smooth muscle cell proliferationGO:190470711.2JAK2, TERT
16transcription from RNA polymerase II promoterGO:000636610.7CEBPA, ETV6, GATA2, NPM1, RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:000551512.0CEBPA, CHIC2, DNMT3A, ETV6, FLT3, GATA2
2metal ion bindingGO:004687211.8DNMT3A, GATA2, IDH1, IDH2, JAK2, KIT
3isocitrate dehydrogenase (NADP+) activityGO:000445011.4IDH1, IDH2
4isocitrate dehydrogenase activityGO:000444811.4IDH1, IDH2
5protein homodimerization activityGO:004280310.8CEBPA, FLT3, IDH1, KIT, NPM1, TERT

Sources for Leukemia, Acute Myeloid

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet